Drugs News

Text Size

May 2012

Anti-HIV Drug Use During Pregnancy Does Not Affect Infant Size, Birth Weight

April 2012

FDA Approves New Pediatric Dosing Recommendations for Fosamprenavir

FDA Issues Safety Announcement on Interactions Between Boceprevir and Certain PIs

March 2012

FDA Approves New Pediatric Dosing Recommendations for Etravirine

December 2011

FDA Expands Use of HIV Drug Isentress to Children and Adolescents

FDA Expands Use of Isentress to Children & Adolescents

Short Course INH-RPT in Patients Taking ARVs

November 2011

Cholesterol Levels Elevated In Toddlers Taking Anti-HIV Drugs

Isentress (raltegravir) package insert updated

August 2011

Supplemental Information Regarding the Role of Rilpivirine (RPV) as Initial Therapy - August 16, 2011

Approval of Complera: emtricitabine/rilpivirine/tenofovir DF fixed dose combination - August 10, 2011

Fluconazole and birth defects - chronic use in pregnancy (outside of vaginal candidiasis) now FDA pregnancy class D - August 4, 2011

July 2011

CDC Trial and Another Major Study Find PrEP Can Reduce Risk of HIV Infection among Heterosexuals - July 13, 2011

May 2011

Approval of generic formulation of lamivudine and zidovudine tablets, 150 mg/300 mg - May 25, 2011

Approval of Edurant (rilpivirine), a new NNRTI, for the Treatment of HIV in Treatment Naive Patients - May 20, 2011

Treating HIV-infected People with Antiretrovirals Protects Partners from Infection - May 12, 2011

April 2011

Update to Fuzeon (enfuvirtide) label regarding incidence of bacterial pneumonia - April 28, 2011

The FEM-PrEP HIV Prevention Study and Its Implications for NIAID Research - April 18, 2011

March 2011

NIH Study Examines Best Time for Healthy HIV-infected People to Begin Antiretrovirals - March 7, 2011

Safety Review update of Abacavir: no statistically significant association seen between myocardial infarction and ABC - March 1, 2011

February 2011

Kaletra (lopinavir/ritonavir) Oral Solution label changes related to toxicity in preterm neonates - February 24, 2011

Viracept (nelfinavir) Label change reflects drug-drug interaction information with warfarin - February 24, 2011

Important information about alcohol prep pads packaged with Fuzeon and certain other injection products - February 8, 2011

Reyataz (atazanavir) label revised, adding dosing recommendations for pregnancy and postpartum period - February 4, 2011

December 2010

New Intelence (etravirine) dosage approved - December 22, 2010

November 2010

FDA approves Egrifta to treat Lipodystrophy in HIV patients - November 10, 2010

FDA Approves Egrifta to Treat Lipodystrophy in HIV Patients - November 10, 2010

NIH Network Identifies Better Treatment Regimen for HIV-Infected Infants - November 3, 2010

October 2010

FDA Drug Safety Communication: Invirase (saquinavir) labels now contain updated risk information on abnormal heart rhythms - October 21, 2010

Invirase (saquinavir) labels now contain updated risk information on abnormal heart rhythms - October 21, 2010

September 2010

FDA Drug Safety Communication: New dosing recommendations to prevent potential Valcyte (valganciclovir) overdose in pediatric transplant patients

New dosing recommendations to prevent potential Valcyte (valganciclovir) overdose in pediatric transplant patients - September 15, 2010

July 2010

NIH-Funded Study Finds Early HAART during TB Treatment Boosts Survival Rate in People Co-Infected with HIV and TB - July 22, 2010

NIH Scientist Anthony S. Fauci to Address Early HIV Infection and a Novel Target for HIV Vaccine Development - July 20, 2010

Increased Use of Treatment Leads to Reduction in New Diagnoses

June 2010

Isentress (raltegravir potassium) label update reflects 96 week safety/efficacy results in treatment-naive and treatment-experienced patients - June 30, 2010

Isentress (raltegravir potassium) label update reflects 96 week safety/efficacy results in treatment-naive and treatment-experienced patients

May 2010

Selzentry (maraviroc) labeling changes for patients with renal impairment

April 2010

New Kaletra (lopinavir/ritonavir) Tablets and Oral Solution once daily dosing regimen in certain adult patients

New Kaletra (lopinavir/ritonavir) Tablets and Oral Solution once daily dosing regimen in certain adult patients - April 28, 2010

New label information affecting all approved protease inhibitors for treatment of HIV

Updated label information for Sustiva (efavirenz)

March 2010

Intelence (etravirine) label revised to include new drug-drug interaction information - March 11, 2010

February 2010

Ongoing safety review of Invirase (saquinavir) and possible association with abnormal heart rhythms - February 23, 2010

Ongoing safety review of Invirase (saquinavir) and possible association with abnormal heart rhythms - February 23, 2010

Kaletra (lopinavir/ritonavir) package insert revision regarding drug-drug interaction information - February 1, 2010

January 2010

FDA Drug Safety Communication: Serious liver disorder associated with the use of Videx/Videx EC (didanosine)

Serious Liver Disorder Associated with the use of Videx/Videx EC (didanosine) - January 29, 2010

Prezista (darunavir) labeling changes reflect 96 week study data - January 27, 2010

Atripla label update reflects new efficacy, safety and resistance data in treatment experienced patients - January 7, 2010

December 2009

Important information about Lexiva (fosamprenavir calcium) Tablets and Oral Suspension - December 4, 2009

Tenofovir/ Emtricitabine Performs Better than Abacavir/ Lamivudine in Subgroup of Antiretroviral-Naïve, HIV-Infected Individuals - December 2, 2009

Tenofovir/Emtricitabine Performs Better than Abacavir/Lamivudine in Subgroup of Antiretroviral-Naïve, HIV-Infected Individuals

November 2009

Intelence (etravirine) label updated to reflect dosing data through 48 weeks - 25 November, 2009

Important label update for Norvir (ritonavir) - November 24, 2009

Expanded indication for Selzentry (maraviroc) - November 24, 2009

New dosing recommendations Retrovir (zidovudine) syrup for HIV-infected infants - November 10, 2009

New dosing recommendations Retrovir (zidovudine) syrup for HIV-infected infants - November 10, 2009

August 2009

FDA Issues a Safety Warning for Etravirine - August 26, 2009

June 2009

Starting Antiretroviral Therapy Earlier Yields Better Clinical Outcomes : Interim Review Leads to Early End of Clinical Trial in Haiti

February 2009

IL-2 Immunotherapy Fails to Benefit HIV-Infected Individuals Already Taking Antiretrovirals

Anti-HIV Gel Shows Promise in Large-scale Study in Women

August 2008

Anti-HIV `Drug Cocktails¿ Equally Effective in Patients with or without History of Injection Drug Use

NIDA: HAART Equally Effective in Patients with or without History of Injection Drug Use - August 6, 2008

May 2008

Dear Healthcare Professional Letter Issued: Important Information for Prescribers about Viracept (Nelfinavir) - May 9, 2008

April 2008

Adult Guidelines Panel Issues a Communication on Abacavir - April 4, 2008

January 2008

FDA Approves New NNRTI, Etravirine - January 18, 2008

FDA Approves New HIV Drug After Priority Review

October 2007

FDA Approves the First Integrase Inhibitor, Raltegravir - October 12, 2007

September 2007

FDA Antiviral Drugs Advisory Committee Recommends Accelerated Approval of Raltegravir - September 5, 2007

DHHS Perinatal Panel Notice on Nelfinavir FDA-Pfizer Letter - September 11, 2007

HIV Protease Inhibitors Show Potential as Cancer Treatments

August 2007

FDA Approves HIV-Entry Inhibitor Maraviroc - August 6, 2007

Approval of maraviroc

July 2007

Treating HIV-Infected Infants Early Helps Them Live Longer

June 2007

FDA approval of Lexiva oral suspension and label changes for pediatric patients and patients with hepatic impairment

May 2007

NIDA Looks at Non-Injection Drug Use and Spread of HIV/AIDS

April 2007

FDA Advisory Committee Recommends Accelerated Approval of HIV Entry Inhibitor, Maraviroc - April 24, 2007

FDA Grants Tentative Approval to Generic Formulation of Stavudine - April 24, 2007

Product Labeling for Kaletra (lopinavir/ritonavir) Updated with New Safety and Efficacy Data - April 24th, 2007

Important Notice about Combivir and Ziagen

March 2007

FDA Strengthens Safety Information for Erythropoiesis-Stimulating Agents (ESAs)-March 9, 2007

February 2007

NIH Release--New Paradigm Will Help Identify Leads for Drug Discovery--July 24, 2006

NIH Release--New Paradigm Will Help Identify Leads for Drug Discovery--July 24, 2006

January 2007

WOMEN'S RESPONSE TO ANTI-HIV THERAPY IMPROVED IF TREATMENT BEGINS SIX MONTHS AFTER EARLIER PREVENTIVE REGIMEN

NIH Release--Women's Response to Anti-HIV Therapy Improved If Treatment Begins Six Months After Earlier Preventive RegimenResponse to Treatment Diminished If Treatment Begins Within Six Months Of Preventive Regimen, January 10, 2007

November 2006

International HIV/AIDS Trial Finds that Risks of Death, AIDS and Other Major Diseases Increase on Episodic Antiretroviral Therapy

Atazanavir Labeling Changes

October 2006

Food and Drug Administration Approved New 300 mg Capsule Form of Reyataz--October 16, 2006

July 2006

Tentative approval of lamivudine/zidovudine copackaged with abacavir sulfate

FDA Approves the First Once-a-Day Three-Drug Combination Tablet for Treatment of HIV-1

June 2006

FDA Grants Tentative Approval of a Three-Component AIDS Drug

Important safety information about Aptivus ( tipranavir)

FDA Approves New HIV Treatment for Patients Who Do Not Respond to Existing Drugs

FDA Gives Tentative Approval for Another First Time Generic Pediatric AIDS Drug in Association with the President's Emergency Plan for AIDS Relief

FDA Approval of Prezista

FDA Approval of Prezista--June 26, 2006

FDA--GARDASIL: Questions and Answers--June 8, 2006

FDA Release--New Guidance on Antiviral Product Development--June 9, 2006

AIDS Drugs Have Saved 3 Million Years of Life in the United States--NIH Press Release, June 2, 2006

March 2006

Generic zidovudine in Capsule Form

FDA Grants Traditional Approval of Viread and Truvada--March 8, 2006

Traditional Approval of Viread and Truvada

January 2006

FDA Label Changes for Atazanavir--January 30, 2006

FDA Announces New Prescription Drug Information Format to Improve Patient Safety--January 19, 2006

International HIV/AIDS Trial Finds Continuous Antiretroviral Therapy Superior to Episodic Therapy

Strategies for Management of Anti-Retroviral Therapy (SMART) Trial Q & A's--January 18, 2006

November 2005

FDA approves New Formulation of Kaletra--October 28, 2005

October 2005

FDA approval of new formulation of Kaletra

September 2005

Emtriva: New Formulation and Labeling Changes

FDA Approves First Pediatric Generic AIDS Drug for U.S. Marketing

Tentative Approval Generic Zidovudine Oral Solution

June 2005

FDA Approval of Aptivus (tipranavir)

FDA Tentatively Approves First Generic Nevirapine under the President's Emergency Plan for AIDS Relief

FDA Tentatively Approves a Generic AIDS Drug under the President's Emergency Plan for AIDS Relief

May 2005

FDA Approves Generic Version of Foscavir

Dear Health Care Provider Letter Regarding the Discontinuation of Fortovase

April 2005

FDA Approves Once-Daily Dosage of Kaletra for Therapy-Naïve Adult Patients

FDA Approved the use of KALETRA, Once-daily Administration for the Treatment of HIV-infection in Therapy-naïve Adults--April 29,2005

Important Change in SUSTIVA (efavirenz) Package Insert — Change from Pregnancy Category C to D--March 31, 2005

January 2005

FDA Public Health Advisory for Nevirapine (Viramune)-January 19, 2005

December 2004

New 500 mg Tablet Formulation of Invirase (saquinavir) Approved

New information about coadministration of REYATAZ (atazanavir) and Norvir (ritonavir) with Prilosec (omeprazole) - December 20, 2004

FDA approves generic formulation of didanosine (ddI) delayed release capsules

Treating Opportunistic Infections Among HIV-Exposed and Infected Children - November 23, 2004

Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents - December 17, 2004

August 2004

FDA Approves Sculptra for HIV Patients

FDA Approves Two Fixed-Dose Combination Drug Products For the Treatment of HIV-1 Infection

July 2004

Researchers Identify Better Hepatitis C Treatment for People with HIV

May 2004

Weekly Cycles of Once-Daily Anti-Drugs Could Reduce Cost of HIV Treatment

Weekly Cycles of Once-Daily Anti-Drugs Could Reduce Cost of HIV Treatment

HHS Proposes Rapid Process For Review of Fixed Dose Combination and Co-Packaged Products

Label Changes for Crixivan - May 2004

Guidance for Industry: Fixed Dose Combination and Co-Packaged Drug Products for Treatment of HIV

April 2004

HIV Patients Get Long-Term Boost with Short, Intermittent Drug Regimen

Joint Statement Issued Regarding Principles For Fixed-Dose Combination Drug Products

January 2004

FDA Issues Draft Guidance on Providing More Information on Investigational Treatment

Drug errors involving Keppra and Kaletra

December 2003

Combination, Order of Anti-HIV Drugs Make a Difference in First-time Recipients

Revisions to Kaletra (lopinavir/ritonavir) labeling

October 2003

FDA Approves LEXIVA (Fosamprenavir calcium) to Treat HIV Infection

Drug Warning: Once-daily Triple NRTI Regimen containing Didanosine, Lamivudine, and Tenofovir

New Live Attenuated Influenza Vaccine (FluMist) Not Recommended for People with HIV or their Close Contacts

September 2003

Nevirapine Sustains Advantage Over AZT During Breastfeeding Period

August 2003

Treatment Interruption Shows No Benefit in Drug-Resistant HIV Infection

Important New Pharmacokinetic Data for REYATAZ(tm) (atazanavir sulfate) in combination with Viread® (tenofovir disoproxil fumarate)

July 2003

CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection

Revised Guidelines Will Ease Selection of HIV/AIDS Treatments

June 2003

FDA Approves a Once Daily Protease Inhibitor for HIV Infection

March 2003

Discovery Lays Groundwork for Potential New Class of Anti-HIV Drugs

Important Interim Results from a Phase III, Randomized, Double-Blind Comparison of Three Protease-Inhibitor-Sparing Regimens for the Initial Treatment of HIV Infection (AACTG Protocol A5095)

FDA Approves First Drug in New Class of HIV Treatments

January 2003

FDA Proposes New Warning for Over-The-Counter Contraceptive Drugs Containing Nonoxynol-9

Preventive Therapy for Non-Occupational Exposures

December 2002

Food and Drug Administration approved a new, extended release formulation of ZERIT

Bush Administration will Seek New Legislation for Mandatory Pediatric Drug Testing

September 2002

Study Sheds Light on Cause of an AIDS Treatment Side Effect

July 2002

Majority of HIV-Infected Mothers and At-Risk Newborns Receive ZDV Treatment in Groundbreaking Thailand Prevention Program

June 2002

Study Concludes Benefits of Anti-HIV Therapy During Pregnancy Outweigh Risks

December 2001

Garlic Supplements Can Impede HIV Medication

7-Day-On, 7-Day-Off Regimen Could Reduce Cost, Toxicities of HIV Therapy

November 2001

New Finding May Help Doctors Prevent HIV Drug Resistance

October 2001

FDA Approves Viread for HIV-1 Infection

April 2001

Use of Antifungal Drug Fluconazole Effective in Preventing Thrush in Persons Who are HIV Positive

January 2001

FDA/Bristol Myers Squibb Issues Caution for HIV Combination Therapy with Zerit and Videx in Pregnant Women

November 2000

FDA Approves Trizivir for HIV

October 2000

Interleukin-2 May Help Patients With Advanced HIV Disease, New Study Shows

Shorter AZT Treatment Reduces Mother to Child HIV Transmission As Well As Longer Treatment But For Less Cost

September 2000

FDA Approves Kaletra for HIV Infection

Statement from Claude Lenfant, M.D., Director, National Heart, Lung, & Blood Institute, on AZT and Cardiac Damage in Infants

July 2000

Inexpensive AIDS Drug Still Reduces HIV Transmission from Mother to Child After One Year

UPDATE ON CLINICAL TRIALS OF INTERLEUKIN-2 (IL-2) AS IMMUNE-BASED THERAPY FOR HIV

March 2000

NIAID Topical Microbicide Research Developing New Tools to Protect Women from HIV/AIDS and Other STDs

February 2000

NIH Clinical Center Study Demonstrates Dangerous Interaction Between St. John's Wort and an HIV Protease Inhibitor

October 1999

NIAID Study: Rapid Rebound of HIV and Reappearance of HIV Reservoirs in Patients Treated with IL-2 and Combination Antiretroviral Drugs Following Cessation of Therapy

New Model Suggests That AIDS Drugs May Not Abolish HIV Infection

July 1999

Researchers Identify a Simple, Affordable Drug Regimen That is Highly Effective in Preventing HIV Infection in Infants of Mothers with the Disease

Attacking AIDS with a 'Cocktail' Therapy: Drug Combo Sends Deaths Plummeting

June 1999

Scientists Suggest New Approaches for Development of AIDS Drugs and Vaccines

May 1999

New Anti-HIV Therapies Needed To Eradicate HIV

April 1999

FDA Approves Amprenavir for HIV Infection

January 1999

Reassuring Findings About Infants Exposed to Zidovudine

December 1998

FDA Approves Abacavir for HIV-1 Infection

Protease Inhibitors May Increase Blood Glucose in HIV Patients

November 1998

Treatment With IL-2 Plus HAART Markedly Reduces HIV in Immune System 'Hiding Places'

October 1998

Information About the Safety of Combination Antiretroviral Treatment for Human Immunodeficiency Virus Infection During Pregnancy

September 1998

Study Shows Efavirenz Promising in Treating Pediatric HIV Infection: Leads to Approval of New Drug for Treating HIV-infected Children

Scientist Report New Strategy to Rapidly Assess Effectiveness of AIDS Drugs in Children

FDA Approves New Drug to Treat HIV, AIDS

July 1998

The Perils of Discontinuing Therapy: Without HAART, Cytokines Stimulate HIV From Latently Infected Cells

June 1998

Short Course of AZT Given Late in Pregnancy and During Delivery Contributes to Reducing Mother-to-Child HIV Transmission

Interleukin-12 Helps Control Mycobacterium Avium Infection

February 1998

Short-Course Regimen of AZT Proven Effective in Reducing Perinatal HIV Transmission: Offers Hope for Reducing Mother-to-Child HIV Transmission in Developing World

Statement by Donna E. Shalala, Secretary of Health and Human Services, Regarding Findings of Thailand Study of 'Short Course' AZT.

Short-Course TB Prophylaxis Effective in HIV-Infected Individuals

January 1998

3-D Structure of HIV Components May Pave the Way for New Anti-AIDS Drugs

November 1997

FDA Approves New Formulation of First Protease Inhibitor Saquinavir

September 1997

FDA Approves First Combination Drug for AIDS

July 1997

New Side Effects of Popular AIDS Drug Reported

June 1997

TB Prophylaxis Unnecessary in HIV-Infected People with Anergy, Study Suggests

Two Drugs Better Than One for Treating Children with Symptomatic HIV

Approved Therapies for HIV/AIDS or AIDS-related Conditions

Study Of Low-dose Oral Alpha Interferon Closes

Health Advisory For Newest Class Of Aids Drugs

Diabetes and Hyperglycemia in Patients Receiving Protease Inhibitors

CDC Statement On Post-exposure Prophylaxis For Exposures To HIV

CDC Studies of AZT to Prevent Mother-to-Child HIV Transmission in Developing Countries

May 1997

Combination Drug Therapy for AIDS Found to Control Blinding Eye Infection

Study Shows That Doxil is Highly Effective and Safe in the Treatment of Advanced Kaposi's Sarcoma

Grapefruit Juice Study May Aid Drug Safety

April 1997

NIAID Evaluates N-9 Film as Microbicide

March 1997

IL-2 Injections Safely Boost CD4+ T Cell Levels in HIV-Infected Patients

FDA Approves First Protease Inhibitors With Labeling for Use in Children

FDA Proposes New Use Initiative

January 1997

Scientists to Discuss Chemokine Receptor Research

Summary of the Meeting of a Panel to Review Studies of Transplacental Toxicity of AZT

November 1996

New ACTG 076 Analysis Emphasizes Importance of Offering AZT Therapy to All HIV-Infected Pregnant Women

Important Information on the Combination of Zidovudine (ZDV) and Stavudine (d4T) in ZDV-experienced HIV-Infected Patients

October 1996

IL-2 Therapy Doubles CD4+ T Cell Counts in HIV-Infected People

Notice to Readers: Clinical Update: Impact of HIV Protease Inhibitors on the Treatment of HIV-Infected Tuberculosis Patients with Rifampin

September 1996

Interleukin-2 Continues to Show Promise as HIV Therapy

Nevirapine Approved by FDA: First non-nucleoside reverse transcriptase inhibitor

Drug Combo Safe for HIV-Infected Children

Volunteers Sought for HIV Treatment Study

August 1996

FDA Approves Drug for AIDS Wasting

NIH-Sponsored Study Stopped: New Drug Does Not Control AIDS-Related Eye Disease

TB Increases HIV Replication in HIV-Infected People

July 1996

Important Therapeutic Information on the Dosing of Clarithromycin for the Treatment of Disseminated Mycobacterium avium Complex (DMAC) Infection in HIV-Infected Patients

Fluconazole Prevents Yeast Infections in Women with HIV

Interleukin-2 Injections Produce Dramatic, Sustained Increases in CD4+ T Cell Counts in Patients with Early-Stage HIV Disease

NIAID Study Rules Out High-Dose Clarithromycin for AIDS-Related MAC

IL-2 Therapy: Encouraging Data on Quality of Life Reported for Immune-Boosting Drug

The Protease Inhibitors

June 1996

FDA Approves Cidofovir for AIDS-Related Retinitis

FDA Approves Nevirapine to Treat HIV

Expanded Access and Expedited Approval of New Therapies Related to HIV/AIDS

Antiretrovirals Plus Immunomodulators: Didanosine/Interferon-alpha Combination Shows Promise

May 1996

An FDA Guide to Choosing Medical Treatments

April 1996

Low-Dose Oral Alpha Interferon Study Opens

Two New Protease Inhibitors Approved By FDA: NIAID Research Was Pivotal to Development of New Class of Drugs

March 1996

FDA Grants Accelerated Approval To Third Protease Inhibitor To Treat HIV

FDA Panel Recommends Approval of Third Protease Inhibitor

FDA Approves Second Protease Inhibitor to Treat HIV

February 1996

Where Do HIV/AIDS Drugs Come From?

January 1996

Two-Drug Treatment is Effective Against Recurrent Eye Infection in AIDS Patients

December 1995

FDA Approves First Protease Inhibitor Drug for Treatment of HIV

November 1995

FDA Grants Accelerated Approval for 3TC with AZT to Treat AIDS

Drug Completely Protects Monkeys Exposed to SIV

FDA Panel Recommends Approval of New AIDS Drug

FDA Panel Recommends Approval of 3TC with AZT to Treat AIDS

October 1995

Thalidomide Effective Treatment for AIDS-Related Mouth Ulcers

April 1995

NIAID Expands Research on Topical Microbicides to Prevent STDs in Women

March 1995

Therapies for AIDS-Related Infections--Two Studies Published

Toxoplasmosis

Questions and Answers about the NIAID Interleukin-2 Study

Interleukin-2 Produces Significant, Sustained Increases in CD4+ T Cells in HIV-Infected People

Toxoplasmosis

February 1995

ARAC Reaffirms Need for Low-Dose Oral Alpha Interferon Study

Interim Results Lead to Discontinuation of AZT-Only Study Arm

December 1994

Oral Ganciclovir Approved

Treatment IND for AIDS-related Wasting Authorized

November 1994

NIAID Trial of Triple Drug Combination for HIV Infection Closes

August 1994

AZT Approved for Preventing Maternal-Fetal HIV Transmission

Recommendations of the U.S. Public Health Service Task Force on the Use of Zidovudine to Reduce Perinatal Transmission of Human Immunodeficiency Virus

Questions and Answers for Publication of 'Recommendations of the U.S. Public Health Service Task Force on the Use of Zidovudine to Reduce Perinatal Transmission of Human Immunodeficiency Virus'

June 1994

FDA Approval of Stavudine (d4T)

May 1994

Task Force to Study Implications of AZT in Pregnancy

April 1994

Effectiveness in Disease and Injury Prevention: Zidovudine for the Prevention of HIV Transmission from Mother to Infant

February 1994

Important Therapeutic Information on the Benefit of Zidovudine for the Prevention of the Transmission of HIV from Mother to Infant

AZT Reduces Rate of Maternal Transmission of HIV

January 1994

FDA Licenses IGIV For Two New Indications

December 1993

Trimetrexate Approved For Treatment of PCP

Fluconazole Delays Fungal Infections In AIDS Patients

Primary Therapy Prevents Initial Bout of PCP

October 1993

AIDSTRIALS and AIDSDRUGS

July 1993

Two Studies Examine Drugs to Prevent HIV-Associated Opportunistic Infections

June 1993

Trial of TAT Antagonist as Therapy for HIV Infection Altered

Relative Benefit of ddI and AZT Depends on Duration of Patients' Previous AZT Use

The Effectiveness of AZT Alone, ddC Alone or AZT/ddC Combination Is Similar Overall For Patients with Advanced HIV Disease

Relative Benefit of ddI and AZT Depends on Duration of Patients' Previous AZT Use

ACTG 116B/117: High Levels of AZT Resistance May Predict HIV Disease Progression

May 1993

Atovaquone Effective, Well-Tolerated Treatment for AIDS-Related Pneumonia

NIAID Opens Combination Therapy Trial for HIV Infection

April 1993

Partial Results of AZT Study Reported in Lancet

March 1993

NIAID Launches HIV Therapy Trial of Protease Inhibitor

NIAID Begins Study of New Drug for HIV Infection

February 1993

Results of Trial of ddI in Patients Intolerant of AZT Announced

Important Therapeutic Information on Treatment of HIV Infection in HIV-Infected Patients Who Are Intolerant of or Have Failed Zidovudine Therapy

Clinical Alert: Important Therapeutic Information on Treatment of HIV Infection in HIV-Infected Patients Who Are Intolerant of or Have Failed Zidovudine Therapy

January 1993

Patients' Own Immune Cells Used in Experimental HIV Therapy

December 1992

FDA Approves New Indication For Dronabinol

TMP/SMX Better than Aerosolized Pentamidine for Preventing Recurrent PCP

Rifabutin Approval

November 1992

Multi-Site Trial Begins of the Anti-AIDS Drug, Tat Antagonist

Atovaquone Receives Approval for Treatment of PCP

October 1992

First AIDS Drug Tested Under Parallel Track Policy; other d4T related press releases

ddI Receives Additional Approval

August 1992

Switch To ddI From AZT Appears to Slow Progression of HIV Disease

June 1992

Approval of Zalcitabine

April 1992

Advisory Committee Recommends Approval of ddC as Combination AIDS Therapy

Early Use of AZT Reduces Risk of Death

Summary of Preliminary Analysis of Study Comparing ddI and ZDV

January 1992

Study Shows Promise of Fluconazole for Treatment of AIDS-Related Cryptococcal Meningitis

December 1991

ACTG 106: AZT/ddC Combination Shows Benefits for Patients with Advanced HIV Disease

November 1991

Atovaquone (566C80) Receives Treatment IND Status for AIDS Related Use

October 1991

HHS Secretary Louis W. Sullivan announces FDA's approval of ddI.

January 1991

Epoetin Alfa For AIDS Related Condition

May 1990

AZT for Children

March 1990

Expanded Labeling for AZT

March 1987

Approval of AZT